nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—ABCG2—Topotecan—cervical cancer	0.447	1	CbGbCtD
Cladribine—POLE4—renal system—cervical cancer	0.0105	0.0355	CbGeAlD
Cladribine—POLE2—endometrium—cervical cancer	0.00885	0.03	CbGeAlD
Cladribine—POLE2—mammalian vulva—cervical cancer	0.00856	0.0291	CbGeAlD
Cladribine—POLE4—female reproductive system—cervical cancer	0.00839	0.0285	CbGeAlD
Cladribine—Myelosuppression—Topotecan—cervical cancer	0.008	0.0602	CcSEcCtD
Cladribine—Mucosal inflammation—Topotecan—cervical cancer	0.00677	0.051	CcSEcCtD
Cladribine—POLE2—female gonad—cervical cancer	0.00667	0.0226	CbGeAlD
Cladribine—POLE2—vagina—cervical cancer	0.00663	0.0225	CbGeAlD
Cladribine—POLE2—Global Genomic NER (GG-NER)—ERCC1—cervical cancer	0.0066	0.0527	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—POU4F1—cervical cancer	0.00645	0.0515	CbGpPWpGaD
Cladribine—Febrile neutropenia—Topotecan—cervical cancer	0.00623	0.0469	CcSEcCtD
Cladribine—NR5A1—Nuclear Receptors—RARB—cervical cancer	0.0062	0.0494	CbGpPWpGaD
Cladribine—PNP—renal system—cervical cancer	0.00579	0.0196	CbGeAlD
Cladribine—RRM2B—uterine cervix—cervical cancer	0.00574	0.0195	CbGeAlD
Cladribine—RRM2B—decidua—cervical cancer	0.00547	0.0186	CbGeAlD
Cladribine—POLE3—uterine cervix—cervical cancer	0.00543	0.0184	CbGeAlD
Cladribine—RRM2B—renal system—cervical cancer	0.00537	0.0182	CbGeAlD
Cladribine—Interstitial lung disease—Topotecan—cervical cancer	0.0053	0.0399	CcSEcCtD
Cladribine—POLE2—Transcription-coupled NER (TC-NER)—ERCC1—cervical cancer	0.00528	0.0421	CbGpPWpGaD
Cladribine—RRM2B—endometrium—cervical cancer	0.0052	0.0176	CbGeAlD
Cladribine—POLE3—decidua—cervical cancer	0.00517	0.0176	CbGeAlD
Cladribine—PNP—uterus—cervical cancer	0.00516	0.0175	CbGeAlD
Cladribine—POLE3—renal system—cervical cancer	0.00508	0.0172	CbGeAlD
Cladribine—RRM2B—mammalian vulva—cervical cancer	0.00503	0.0171	CbGeAlD
Cladribine—POLE3—endometrium—cervical cancer	0.00491	0.0167	CbGeAlD
Cladribine—NR5A1—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.0049	0.0391	CbGpPWpGaD
Cladribine—Rash erythematous—Topotecan—cervical cancer	0.0049	0.0368	CcSEcCtD
Cladribine—POLE2—Nucleotide Excision Repair—ERCC1—cervical cancer	0.00485	0.0387	CbGpPWpGaD
Cladribine—POLE3—mammalian vulva—cervical cancer	0.00475	0.0161	CbGeAlD
Cladribine—PNP—female reproductive system—cervical cancer	0.00464	0.0157	CbGeAlD
Cladribine—RRM1—E2F transcription factor network—YY1—cervical cancer	0.00453	0.0361	CbGpPWpGaD
Cladribine—SLC28A3—mammalian vulva—cervical cancer	0.00445	0.0151	CbGeAlD
Cladribine—RRM2B—female reproductive system—cervical cancer	0.0043	0.0146	CbGeAlD
Cladribine—Extravasation—Topotecan—cervical cancer	0.0043	0.0323	CcSEcCtD
Cladribine—POLE2—lymph node—cervical cancer	0.00429	0.0146	CbGeAlD
Cladribine—POLE—Global Genomic NER (GG-NER)—ERCC1—cervical cancer	0.00425	0.0339	CbGpPWpGaD
Cladribine—PNP—female gonad—cervical cancer	0.00422	0.0143	CbGeAlD
Cladribine—POLE—uterine cervix—cervical cancer	0.00414	0.0141	CbGeAlD
Cladribine—POLE3—female reproductive system—cervical cancer	0.00407	0.0138	CbGeAlD
Cladribine—Blood bilirubin increased—Topotecan—cervical cancer	0.00397	0.0298	CcSEcCtD
Cladribine—POLE—decidua—cervical cancer	0.00395	0.0134	CbGeAlD
Cladribine—NR5A1—female reproductive system—cervical cancer	0.00394	0.0134	CbGeAlD
Cladribine—RRM2B—female gonad—cervical cancer	0.00392	0.0133	CbGeAlD
Cladribine—Bone pain—Topotecan—cervical cancer	0.00392	0.0295	CcSEcCtD
Cladribine—RRM2B—vagina—cervical cancer	0.00389	0.0132	CbGeAlD
Cladribine—Pulmonary embolism—Topotecan—cervical cancer	0.00375	0.0282	CcSEcCtD
Cladribine—POLE—endometrium—cervical cancer	0.00375	0.0127	CbGeAlD
Cladribine—RRM2—E2F transcription factor network—YY1—cervical cancer	0.00373	0.0298	CbGpPWpGaD
Cladribine—POLE3—female gonad—cervical cancer	0.0037	0.0126	CbGeAlD
Cladribine—POLE3—vagina—cervical cancer	0.00368	0.0125	CbGeAlD
Cladribine—RRM1—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.00366	0.0292	CbGpPWpGaD
Cladribine—POLE—mammalian vulva—cervical cancer	0.00362	0.0123	CbGeAlD
Cladribine—NR5A1—female gonad—cervical cancer	0.00359	0.0122	CbGeAlD
Cladribine—POLA1—uterine cervix—cervical cancer	0.00357	0.0121	CbGeAlD
Cladribine—POLE2—Extension of Telomeres—TERT—cervical cancer	0.00347	0.0277	CbGpPWpGaD
Cladribine—SLC28A3—female gonad—cervical cancer	0.00346	0.0118	CbGeAlD
Cladribine—RRM2—uterine cervix—cervical cancer	0.00341	0.0116	CbGeAlD
Cladribine—POLA1—decidua—cervical cancer	0.0034	0.0115	CbGeAlD
Cladribine—POLE—Transcription-coupled NER (TC-NER)—ERCC1—cervical cancer	0.0034	0.0271	CbGpPWpGaD
Cladribine—Neoplasm—Topotecan—cervical cancer	0.00339	0.0255	CcSEcCtD
Cladribine—Sepsis—Topotecan—cervical cancer	0.00325	0.0245	CcSEcCtD
Cladribine—RRM2—decidua—cervical cancer	0.00325	0.011	CbGeAlD
Cladribine—POLA1—endometrium—cervical cancer	0.00323	0.011	CbGeAlD
Cladribine—RRM2—renal system—cervical cancer	0.00319	0.0108	CbGeAlD
Cladribine—POLE—Nucleotide Excision Repair—ERCC1—cervical cancer	0.00313	0.0249	CbGpPWpGaD
Cladribine—POLA1—mammalian vulva—cervical cancer	0.00312	0.0106	CbGeAlD
Cladribine—POLE—female reproductive system—cervical cancer	0.0031	0.0105	CbGeAlD
Cladribine—RRM2—endometrium—cervical cancer	0.00309	0.0105	CbGeAlD
Cladribine—RRM2—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.00301	0.024	CbGpPWpGaD
Cladribine—RRM2—mammalian vulva—cervical cancer	0.00298	0.0101	CbGeAlD
Cladribine—RRM2—uterus—cervical cancer	0.00284	0.00965	CbGeAlD
Cladribine—RRM1—uterine cervix—cervical cancer	0.00283	0.00962	CbGeAlD
Cladribine—POLE—female gonad—cervical cancer	0.00282	0.00959	CbGeAlD
Cladribine—POLE—vagina—cervical cancer	0.00281	0.00953	CbGeAlD
Cladribine—Lethargy—Topotecan—cervical cancer	0.00278	0.0209	CcSEcCtD
Cladribine—RRM1—decidua—cervical cancer	0.0027	0.00916	CbGeAlD
Cladribine—RRM1—renal system—cervical cancer	0.00265	0.009	CbGeAlD
Cladribine—RRM1—endometrium—cervical cancer	0.00256	0.0087	CbGeAlD
Cladribine—RRM1—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.00256	0.0204	CbGpPWpGaD
Cladribine—RRM2—female reproductive system—cervical cancer	0.00256	0.00868	CbGeAlD
Cladribine—POLA1—E2F transcription factor network—YY1—cervical cancer	0.00255	0.0204	CbGpPWpGaD
Cladribine—POLE2—DNA Repair—ERCC1—cervical cancer	0.00253	0.0201	CbGpPWpGaD
Cladribine—RRM2B—lymph node—cervical cancer	0.00252	0.00855	CbGeAlD
Cladribine—SLC22A2—renal system—cervical cancer	0.00249	0.00844	CbGeAlD
Cladribine—RRM1—mammalian vulva—cervical cancer	0.00248	0.00842	CbGeAlD
Cladribine—POLA1—female gonad—cervical cancer	0.00243	0.00826	CbGeAlD
Cladribine—POLA1—vagina—cervical cancer	0.00242	0.00821	CbGeAlD
Cladribine—POLE3—lymph node—cervical cancer	0.00238	0.00808	CbGeAlD
Cladribine—NR5A1—Transcriptional regulation of pluripotent stem cells—STAT3—cervical cancer	0.00237	0.0189	CbGpPWpGaD
Cladribine—RRM1—uterus—cervical cancer	0.00236	0.00802	CbGeAlD
Cladribine—NR5A1—Developmental Biology—INSM1—cervical cancer	0.00235	0.0188	CbGpPWpGaD
Cladribine—RRM2—female gonad—cervical cancer	0.00233	0.00789	CbGeAlD
Cladribine—RRM2—vagina—cervical cancer	0.00231	0.00785	CbGeAlD
Cladribine—RRM2B—DNA Damage Response—CASP8—cervical cancer	0.00226	0.018	CbGpPWpGaD
Cladribine—POLE—Extension of Telomeres—TERT—cervical cancer	0.00224	0.0178	CbGpPWpGaD
Cladribine—Pancytopenia—Topotecan—cervical cancer	0.00223	0.0168	CcSEcCtD
Cladribine—DCK—uterine cervix—cervical cancer	0.0022	0.00747	CbGeAlD
Cladribine—Neutropenia—Topotecan—cervical cancer	0.0022	0.0166	CcSEcCtD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—CASP8—cervical cancer	0.00218	0.0174	CbGpPWpGaD
Cladribine—RRM1—female reproductive system—cervical cancer	0.00212	0.00721	CbGeAlD
Cladribine—Pneumonia—Topotecan—cervical cancer	0.00211	0.0159	CcSEcCtD
Cladribine—RRM2—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.00211	0.0168	CbGpPWpGaD
Cladribine—Infestation—Topotecan—cervical cancer	0.0021	0.0158	CcSEcCtD
Cladribine—Infestation NOS—Topotecan—cervical cancer	0.0021	0.0158	CcSEcCtD
Cladribine—DCK—decidua—cervical cancer	0.0021	0.00712	CbGeAlD
Cladribine—DCK—endometrium—cervical cancer	0.00199	0.00676	CbGeAlD
Cladribine—Hepatobiliary disease—Topotecan—cervical cancer	0.00198	0.0149	CcSEcCtD
Cladribine—Epistaxis—Topotecan—cervical cancer	0.00198	0.0149	CcSEcCtD
Cladribine—RRM1—female gonad—cervical cancer	0.00193	0.00656	CbGeAlD
Cladribine—DCK—mammalian vulva—cervical cancer	0.00193	0.00654	CbGeAlD
Cladribine—RRM1—vagina—cervical cancer	0.00192	0.00652	CbGeAlD
Cladribine—Haemoglobin—Topotecan—cervical cancer	0.00189	0.0142	CcSEcCtD
Cladribine—Haemorrhage—Topotecan—cervical cancer	0.00188	0.0142	CcSEcCtD
Cladribine—Pharyngitis—Topotecan—cervical cancer	0.00187	0.0141	CcSEcCtD
Cladribine—DCK—uterus—cervical cancer	0.00183	0.00623	CbGeAlD
Cladribine—POLE—lymph node—cervical cancer	0.00182	0.00616	CbGeAlD
Cladribine—SLC22A1—renal system—cervical cancer	0.00176	0.00596	CbGeAlD
Cladribine—Angiopathy—Topotecan—cervical cancer	0.00171	0.0129	CcSEcCtD
Cladribine—RRM2B—DNA Damage Response—CASP3—cervical cancer	0.00171	0.0136	CbGpPWpGaD
Cladribine—Immune system disorder—Topotecan—cervical cancer	0.0017	0.0128	CcSEcCtD
Cladribine—Mediastinal disorder—Topotecan—cervical cancer	0.0017	0.0128	CcSEcCtD
Cladribine—Chills—Topotecan—cervical cancer	0.00169	0.0127	CcSEcCtD
Cladribine—POLE2—DNA Repair—SMUG1—cervical cancer	0.00168	0.0134	CbGpPWpGaD
Cladribine—Alopecia—Topotecan—cervical cancer	0.00166	0.0125	CcSEcCtD
Cladribine—DCK—female reproductive system—cervical cancer	0.00165	0.0056	CbGeAlD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—CASP3—cervical cancer	0.00165	0.0131	CbGpPWpGaD
Cladribine—Malnutrition—Topotecan—cervical cancer	0.00164	0.0123	CcSEcCtD
Cladribine—POLE—DNA Repair—ERCC1—cervical cancer	0.00163	0.013	CbGpPWpGaD
Cladribine—POLA1—Extension of Telomeres—TERT—cervical cancer	0.00159	0.0127	CbGpPWpGaD
Cladribine—Back pain—Topotecan—cervical cancer	0.00159	0.0119	CcSEcCtD
Cladribine—POLE2—Telomere Maintenance—TERT—cervical cancer	0.00157	0.0125	CbGpPWpGaD
Cladribine—POLA1—lymph node—cervical cancer	0.00156	0.00531	CbGeAlD
Cladribine—Ill-defined disorder—Topotecan—cervical cancer	0.00152	0.0114	CcSEcCtD
Cladribine—Anaemia—Topotecan—cervical cancer	0.00152	0.0114	CcSEcCtD
Cladribine—DCK—female gonad—cervical cancer	0.0015	0.00509	CbGeAlD
Cladribine—RRM2—lymph node—cervical cancer	0.0015	0.00507	CbGeAlD
Cladribine—DCK—vagina—cervical cancer	0.00149	0.00506	CbGeAlD
Cladribine—Malaise—Topotecan—cervical cancer	0.00148	0.0111	CcSEcCtD
Cladribine—Cough—Topotecan—cervical cancer	0.00143	0.0108	CcSEcCtD
Cladribine—Myalgia—Topotecan—cervical cancer	0.0014	0.0105	CcSEcCtD
Cladribine—Chest pain—Topotecan—cervical cancer	0.0014	0.0105	CcSEcCtD
Cladribine—Arthralgia—Topotecan—cervical cancer	0.0014	0.0105	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00139	0.0104	CcSEcCtD
Cladribine—Discomfort—Topotecan—cervical cancer	0.00138	0.0104	CcSEcCtD
Cladribine—Infection—Topotecan—cervical cancer	0.00133	0.01	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.00132	0.0105	CbGpPWpGaD
Cladribine—Nervous system disorder—Topotecan—cervical cancer	0.00131	0.00987	CcSEcCtD
Cladribine—POLE2—Chromosome Maintenance—TERT—cervical cancer	0.00131	0.0105	CbGpPWpGaD
Cladribine—Thrombocytopenia—Topotecan—cervical cancer	0.00131	0.00986	CcSEcCtD
Cladribine—Skin disorder—Topotecan—cervical cancer	0.0013	0.00978	CcSEcCtD
Cladribine—Hyperhidrosis—Topotecan—cervical cancer	0.00129	0.00973	CcSEcCtD
Cladribine—Anorexia—Topotecan—cervical cancer	0.00128	0.0096	CcSEcCtD
Cladribine—SLC22A1—vagina—cervical cancer	0.00127	0.00432	CbGeAlD
Cladribine—RRM1—lymph node—cervical cancer	0.00124	0.00422	CbGeAlD
Cladribine—ABCG2—uterine cervix—cervical cancer	0.00123	0.00417	CbGeAlD
Cladribine—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00122	0.00917	CcSEcCtD
Cladribine—Paraesthesia—Topotecan—cervical cancer	0.0012	0.00904	CcSEcCtD
Cladribine—Dyspnoea—Topotecan—cervical cancer	0.00119	0.00897	CcSEcCtD
Cladribine—ABCG2—decidua—cervical cancer	0.00117	0.00397	CbGeAlD
Cladribine—Decreased appetite—Topotecan—cervical cancer	0.00116	0.00875	CcSEcCtD
Cladribine—Gastrointestinal disorder—Topotecan—cervical cancer	0.00116	0.00869	CcSEcCtD
Cladribine—Fatigue—Topotecan—cervical cancer	0.00115	0.00868	CcSEcCtD
Cladribine—Constipation—Topotecan—cervical cancer	0.00114	0.00861	CcSEcCtD
Cladribine—Pain—Topotecan—cervical cancer	0.00114	0.00861	CcSEcCtD
Cladribine—ABCG2—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.00113	0.00899	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.00112	0.0089	CbGpPWpGaD
Cladribine—ABCG2—endometrium—cervical cancer	0.00111	0.00377	CbGeAlD
Cladribine—Feeling abnormal—Topotecan—cervical cancer	0.0011	0.0083	CcSEcCtD
Cladribine—Gastrointestinal pain—Topotecan—cervical cancer	0.00109	0.00823	CcSEcCtD
Cladribine—RRM2B—DNA Damage Response—TP53—cervical cancer	0.00109	0.00873	CbGpPWpGaD
Cladribine—POLE—DNA Repair—SMUG1—cervical cancer	0.00108	0.00862	CbGpPWpGaD
Cladribine—ABCG2—mammalian vulva—cervical cancer	0.00107	0.00365	CbGeAlD
Cladribine—Urticaria—Topotecan—cervical cancer	0.00106	0.008	CcSEcCtD
Cladribine—Abdominal pain—Topotecan—cervical cancer	0.00106	0.00796	CcSEcCtD
Cladribine—Body temperature increased—Topotecan—cervical cancer	0.00106	0.00796	CcSEcCtD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—TP53—cervical cancer	0.00106	0.00843	CbGpPWpGaD
Cladribine—ABCG2—uterus—cervical cancer	0.00102	0.00347	CbGeAlD
Cladribine—POLE—Telomere Maintenance—TERT—cervical cancer	0.00101	0.00808	CbGpPWpGaD
Cladribine—Hypersensitivity—Topotecan—cervical cancer	0.000986	0.00742	CcSEcCtD
Cladribine—RRM1—Fluoropyrimidine Activity—TP53—cervical cancer	0.000972	0.00775	CbGpPWpGaD
Cladribine—DCK—lymph node—cervical cancer	0.000965	0.00327	CbGeAlD
Cladribine—Asthenia—Topotecan—cervical cancer	0.00096	0.00722	CcSEcCtD
Cladribine—Pruritus—Topotecan—cervical cancer	0.000947	0.00712	CcSEcCtD
Cladribine—Diarrhoea—Topotecan—cervical cancer	0.000916	0.00689	CcSEcCtD
Cladribine—Dizziness—Topotecan—cervical cancer	0.000885	0.00666	CcSEcCtD
Cladribine—Vomiting—Topotecan—cervical cancer	0.000851	0.0064	CcSEcCtD
Cladribine—NR5A1—Generic Transcription Pathway—RARB—cervical cancer	0.000846	0.00675	CbGpPWpGaD
Cladribine—POLE—Chromosome Maintenance—TERT—cervical cancer	0.000844	0.00674	CbGpPWpGaD
Cladribine—Rash—Topotecan—cervical cancer	0.000844	0.00635	CcSEcCtD
Cladribine—Dermatitis—Topotecan—cervical cancer	0.000843	0.00634	CcSEcCtD
Cladribine—Headache—Topotecan—cervical cancer	0.000838	0.00631	CcSEcCtD
Cladribine—ABCG2—female gonad—cervical cancer	0.000837	0.00284	CbGeAlD
Cladribine—ABCG2—vagina—cervical cancer	0.000832	0.00282	CbGeAlD
Cladribine—RRM2—Fluoropyrimidine Activity—TP53—cervical cancer	0.0008	0.00638	CbGpPWpGaD
Cladribine—Nausea—Topotecan—cervical cancer	0.000795	0.00598	CcSEcCtD
Cladribine—ABCG2—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.000788	0.00629	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.000741	0.00591	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—EGFR—cervical cancer	0.000731	0.00583	CbGpPWpGaD
Cladribine—POLA1—Telomere Maintenance—TERT—cervical cancer	0.000722	0.00576	CbGpPWpGaD
Cladribine—POLE2—G1 to S cell cycle control—TP53—cervical cancer	0.000668	0.00533	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—TP53—cervical cancer	0.000614	0.0049	CbGpPWpGaD
Cladribine—POLA1—Chromosome Maintenance—TERT—cervical cancer	0.000602	0.0048	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—CA9—cervical cancer	0.000578	0.00461	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—NOTCH2—cervical cancer	0.00056	0.00447	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—TP53—cervical cancer	0.000549	0.00438	CbGpPWpGaD
Cladribine—ABCG2—lymph node—cervical cancer	0.000538	0.00183	CbGeAlD
Cladribine—PNP—Metabolism—CA9—cervical cancer	0.000501	0.004	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000492	0.00392	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—TERT—cervical cancer	0.000451	0.0036	CbGpPWpGaD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—TP53—cervical cancer	0.000447	0.00357	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—HES1—cervical cancer	0.000433	0.00345	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—TP53—cervical cancer	0.000431	0.00344	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—RARB—cervical cancer	0.000407	0.00325	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.000372	0.00297	CbGpPWpGaD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—TP53—cervical cancer	0.000368	0.00294	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.000359	0.00286	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—TP53—cervical cancer	0.000354	0.00282	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—NOTCH1—cervical cancer	0.000347	0.00277	CbGpPWpGaD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—TP53—cervical cancer	0.000344	0.00275	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TERT—cervical cancer	0.000333	0.00265	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—NOTCH1—cervical cancer	0.000327	0.0026	CbGpPWpGaD
Cladribine—ABCG2—Fluoropyrimidine Activity—TP53—cervical cancer	0.000299	0.00239	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CA9—cervical cancer	0.000288	0.0023	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	0.000284	0.00227	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000277	0.00221	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—NOTCH2—cervical cancer	0.00027	0.00215	CbGpPWpGaD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—TP53—cervical cancer	0.000252	0.00201	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.000238	0.0019	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CA9—cervical cancer	0.000237	0.00189	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—MTHFR—cervical cancer	0.000235	0.00187	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TERT—cervical cancer	0.000223	0.00178	CbGpPWpGaD
Cladribine—DCK—Metabolism—CA9—cervical cancer	0.000222	0.00177	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—CTNNB1—cervical cancer	0.000217	0.00173	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TERT—cervical cancer	0.000214	0.00171	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.00021	0.00167	CbGpPWpGaD
Cladribine—PNP—Metabolism—MTHFR—cervical cancer	0.000203	0.00162	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.000202	0.00161	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—STAT3—cervical cancer	0.000189	0.00151	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—EGFR—cervical cancer	0.000172	0.00137	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—NOTCH1—cervical cancer	0.000167	0.00133	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	0.00016	0.00128	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TERT—cervical cancer	0.000153	0.00122	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.000134	0.00107	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TP53—cervical cancer	0.000127	0.00101	CbGpPWpGaD
Cladribine—RRM1—Metabolism—MTHFR—cervical cancer	0.000117	0.000932	CbGpPWpGaD
Cladribine—RRM2—Metabolism—MTHFR—cervical cancer	9.62e-05	0.000767	CbGpPWpGaD
Cladribine—DCK—Metabolism—MTHFR—cervical cancer	8.99e-05	0.000717	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CA9—cervical cancer	8.87e-05	0.000707	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CA9—cervical cancer	8.77e-05	0.0007	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—cervical cancer	8.5e-05	0.000678	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CA9—cervical cancer	8.18e-05	0.000652	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—cervical cancer	8.16e-05	0.000651	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—cervical cancer	5.81e-05	0.000464	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—MTHFR—cervical cancer	3.6e-05	0.000287	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—MTHFR—cervical cancer	3.56e-05	0.000284	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—MTHFR—cervical cancer	3.32e-05	0.000265	CbGpPWpGaD
